Castle Biosciences to Release Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call on Tuesday, Feb. 28, 2023

Rhea-AI Summary

Castle Biosciences (NASDAQ: CSTL) announced it will release its fourth quarter and full-year financial results for 2022 after market close on February 28, 2023. A conference call will be held at 4:30 p.m. ET to discuss the results, available via webcast and phone. The company focuses on innovative diagnostics, with a portfolio that includes tests for various cancers and mental health conditions, along with ongoing research programs for additional diseases. For more details, visit Castle's website.

Positive

• Focus on innovative diagnostic tests that guide patient care.
• Active research and development programs for tests in high clinical need.

Negative

• None.

FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the fourth quarter and year ended Dec. 31, 2022, after the close of market on Tuesday, Feb. 28, 2023.

Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day.

Conference Call and Webcast Details

A live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/697513364 or via the webcast link on the Investor Relations page of the Company’s website: https://ir.castlebiosciences.com/overview/default.aspx. Please access the webcast at least 10 minutes before the conference call start time. A replay of the webcast will be available following the conclusion of the conference call.

To access the live conference call via phone, please dial 1 844 200 6205 from the United States, or +1 929 526 1599 internationally, at least 10 minutes prior to the start of the call, using the access code 235869.

There will be a brief Question & Answer session following management commentary.

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.

Castle’s current portfolio consists of tests for skin cancers, uveal melanoma, Barrett’s esophagus and mental health conditions. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to predict systemic therapy response in patients with moderate-to-severe psoriasis, atopic dermatitis and related conditions. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, Twitter and Instagram.

DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq, TissueCypher and IDgenetix are trademarks of Castle Biosciences, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230207006037/en/

Investor Contact:

Camilla Zuckero

czuckero@castlebiosciences.com

Media Contact:

Allison Marshall

amarshall@castlebiosciences.com

Source: Castle Biosciences, Inc.

FAQ

When will Castle Biosciences release its Q4 2022 financial results?

Castle Biosciences will release its Q4 2022 financial results on February 28, 2023.

What time is the Castle Biosciences earnings conference call?

The earnings conference call for Castle Biosciences will be held at 4:30 p.m. ET on February 28, 2023.

Where can I access the Castle Biosciences Q4 2022 financial results?

The financial results can be accessed via a live webcast on the company's investor relations page.

What is the focus of Castle Biosciences?

Castle Biosciences focuses on developing innovative tests for skin cancers, mental health conditions, and other diseases.